Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.

Limagne E, Thibaudin M, Nuttin L, Spill A, Derangère V, Fumet JD, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F.

Cancer Immunol Res. 2019 Dec;7(12):1958-1969. doi: 10.1158/2326-6066.CIR-19-0228. Epub 2019 Oct 14.

PMID:
31611243
2.

Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade.

Limagne E, Nuttin L, Spill A, Thibaudin M, Derangere V, Cattan V, Bruno A, Amellal N, Ghiringhelli F.

Ann Oncol. 2017 Jun;28 Suppl 3:iii90. doi: 10.1093/annonc/mdx261.254. No abstract available.

3.

Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery.

Driessens G, Nuttin L, Gras A, Maetens J, Mievis S, Schoore M, Velu T, Tenenbaum L, Préat V, Bruyns C.

Cancer Immunol Immunother. 2011 Feb;60(2):273-81. doi: 10.1007/s00262-010-0941-y. Epub 2010 Nov 13.

PMID:
21076828
4.

Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.

Driessens G, Gordower L, Nuttin L, Stordeur P, Blocklet D, Egrise D, Velu T, Bruyns C.

Cancer Immunol Immunother. 2008 Dec;57(12):1745-56. doi: 10.1007/s00262-008-0500-y. Epub 2008 Mar 28.

PMID:
18369621

Supplemental Content

Loading ...
Support Center